AU756222B2 - Nucleic acid vaccines encoding G protein of respiratory syncytial virus - Google Patents
Nucleic acid vaccines encoding G protein of respiratory syncytial virus Download PDFInfo
- Publication number
- AU756222B2 AU756222B2 AU84278/98A AU8427898A AU756222B2 AU 756222 B2 AU756222 B2 AU 756222B2 AU 84278/98 A AU84278/98 A AU 84278/98A AU 8427898 A AU8427898 A AU 8427898A AU 756222 B2 AU756222 B2 AU 756222B2
- Authority
- AU
- Australia
- Prior art keywords
- rsv
- protein
- nucleotide sequence
- vector
- host
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 241000725643 Respiratory syncytial virus Species 0.000 title claims description 211
- 108091006027 G proteins Proteins 0.000 title claims description 130
- 102000030782 GTP binding Human genes 0.000 title claims description 130
- 108091000058 GTP-Binding Proteins 0.000 title claims description 130
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 title description 3
- 229940023146 nucleic acid vaccine Drugs 0.000 title description 3
- 239000002773 nucleotide Substances 0.000 claims description 87
- 125000003729 nucleotide group Chemical group 0.000 claims description 87
- 239000013598 vector Substances 0.000 claims description 74
- 230000003053 immunization Effects 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 33
- 230000002163 immunogen Effects 0.000 claims description 27
- 238000001727 in vivo Methods 0.000 claims description 25
- 201000010099 disease Diseases 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- 108090000695 Cytokines Proteins 0.000 claims description 16
- 102000004127 Cytokines Human genes 0.000 claims description 16
- 241000701022 Cytomegalovirus Species 0.000 claims description 15
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 15
- 239000012634 fragment Substances 0.000 claims description 15
- 239000013600 plasmid vector Substances 0.000 claims description 13
- 208000015181 infectious disease Diseases 0.000 claims description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 10
- 238000011144 upstream manufacturing Methods 0.000 claims description 10
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 9
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 9
- 229960000187 tissue plasminogen activator Drugs 0.000 claims description 9
- 108091026890 Coding region Proteins 0.000 claims description 8
- 229940065638 intron a Drugs 0.000 claims description 8
- 230000001681 protective effect Effects 0.000 claims description 7
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 39
- 229960005486 vaccine Drugs 0.000 description 34
- 238000002649 immunization Methods 0.000 description 30
- 239000013612 plasmid Substances 0.000 description 26
- 239000000427 antigen Substances 0.000 description 22
- 102000036639 antigens Human genes 0.000 description 22
- 108091007433 antigens Proteins 0.000 description 22
- 230000003362 replicative effect Effects 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 17
- 241000700605 Viruses Species 0.000 description 16
- 210000004072 lung Anatomy 0.000 description 14
- 239000002671 adjuvant Substances 0.000 description 13
- 230000028993 immune response Effects 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 11
- 230000004044 response Effects 0.000 description 10
- 150000007523 nucleic acids Chemical group 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 230000005847 immunogenicity Effects 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 108091033319 polynucleotide Proteins 0.000 description 7
- 102000040430 polynucleotide Human genes 0.000 description 7
- 239000002157 polynucleotide Substances 0.000 description 7
- 230000004224 protection Effects 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000003472 neutralizing effect Effects 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 101150082239 G gene Proteins 0.000 description 5
- 108010006025 bovine growth hormone Proteins 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 230000005875 antibody response Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000002434 immunopotentiative effect Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 238000011725 BALB/c mouse Methods 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108010002616 Interleukin-5 Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 229940124590 live attenuated vaccine Drugs 0.000 description 3
- 229940023012 live-attenuated vaccine Drugs 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 210000003501 vero cell Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000282579 Pan Species 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 229940124679 RSV vaccine Drugs 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 210000004201 immune sera Anatomy 0.000 description 2
- 229940042743 immune sera Drugs 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000002480 immunoprotective effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 101000605403 Homo sapiens Plasminogen Proteins 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000783356 Naja sputatrix Cytotoxin Proteins 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 108091006088 activator proteins Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 238000009739 binding Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000002340 cardiotoxin Substances 0.000 description 1
- 231100000677 cardiotoxin Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000012568 clinical material Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940090046 jet injector Drugs 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 208000030500 lower respiratory tract disease Diseases 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940031346 monovalent vaccine Drugs 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 238000002962 plaque-reduction assay Methods 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001279 poly(ester amides) Polymers 0.000 description 1
- -1 poly(glycolide) Polymers 0.000 description 1
- 229920001306 poly(lactide-co-caprolactone) Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 201000009732 pulmonary eosinophilia Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000029069 type 2 immune response Effects 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 230000007501 viral attachment Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Description
WO 99/04010 PCT/CA98/00697 TITLE OF INVENTION NUCLEIC ACID VACCINES ENCODING G PROTEIN OF RESPIRATORY SYNCYTIAL VIRUS FIELD OF INVENTION The present invention is related to the field of respiratory syncytial virus (RSV) vaccines and is particularly concerned with vaccines comprising nucleic acid sequences encoding the attachment protein of
RSV.
BACKGROUND OF INVENTION Respiratory syncytial virus (RSV), a negativestrand RNA virus belonging to the Paramyxoviridae family of viruses, is the major viral pathogen responsible for bronchiolitis and pneumonia in infants and young children (ref. 1 Throughout this application, various references are referred to in parenthesis to more fully describe the state of the art to which this invention pertains. Full bibliographic information for each citation is found at the end of the specification, immediately preceding the claims. The disclosures of these references are hereby incorporated by reference into the present disclosure). Acute respiratory tract infections caused by RSV result in approximately 90,000 hospitalizations and 4,500 deaths per year in the United States (ref. Medical care costs due to RSV infection are greater than $340 M annually in the United States alone (ref. There is currently no licensed vaccine against RSV. The main approaches for developing an RSV vaccine have included inactivated virus, liveattenuated viruses and subunit vaccines.
A protective immune response against RSV is thought to require the induction of neutralizing antibodies against the surface fusion and attachment (G) glycoproteins (ref. In addition, cytotoxic T lymphocytes (CTL) responses are involved in viral clearance. The F protein is conserved amongst the RSV A SUBSTITUTE SHEET (RULE 26) WO 99/04010 PCT/CA98/00697 2 and B subgroups.
The G protein (33 kDa) of RSV is heavily 0glycosylated giving rise to a glycoprotein of apparent molecular weight of 90 kDa (ref. Two broad subtypes of RS virus have been defined: A and B (ref. The major antigenic differences between these subtypes are found in the G glycoprotein (refs. 3, 7).
The use of RSV proteins as vaccines may have obstacles. Parenterally administered vaccine candidates have so far proven to be poorly immunogenic with regard to the induction of neutralizing antibodies in seronegative chimpanzees. The serum antibody response induced by these antigens may be further diminished in the presence of passively acquired antibodies, such as the transplacentally acquired maternal antibodies which most young infants possess. A subunit vaccine candidate for RSV consisting of purified fusion glycoprotein from RSV infected cell cultures and purified by immunoaffinity or ion-exchange chromatography has been described (ref. Parenteral immunization of seronegative or seropositive chimpanzees with this preparation was performed and three doses of 50 pg were required in seronegative animals to induce an RSV serum neutralizing titre of approximately 1:50. Upon subsequent challenge of these animals with wild-type RSV, no effect of immunization on virus shedding or clinical disease could be detected in the upper respiratory tract. The effect of immunization with this vaccine on virus shedding in the lower respiratory tract was not investigated, although this is the site where the serum antibody induced by parenteral immunization may be expected to have its greatest effect. Safety and immunogenicity studies have been performed in a small number of seropositive individuals. The vaccine was found to be safe in seropositive children and in three SUBSTITUTE SHEET (RULE 26) WO 99/04010 PCT/CA98/00697 3 seronegative children (all 2.4 years of age). The effects of immunization on lower respiratory tract disease could not be determined because of the small number of children immunized. One immunizing dose in seropositive children induced a 4-fold increase in virus neutralizing antibody titres in 40 to 60% of the vaccinees. Thus, insufficient information is available from these small studies to evaluate the efficacy of this vaccine against RSV-induced disease. A further problem facing subunit RSV vaccines is the possibility that inoculation of seronegative subjects with immunogenic preparations might result in disease enhancement. In the 1960's, vaccination of infants with a formalin-inactivated RSV preparation (FI-RSV) resulted in enhanced lung disease upon subsequent exposure to live virus, also referred to as immunopotentiation (refs. 9, 10). These vaccinees developed strong serological responses, but were not protected against infection and some developed severe, occasionally fatal respiratory tract disease upon natural infection.
Although precise mechanisms remain unknown, it has been suggested that this form of immune enhancement might reflect either structural alterations of RSV antigens (ref. 11), residual serum and/or cellular contaminants (ref. 12), a specific property of the viral attachment protein (refs. 13,14) or an imbalanced cell-mediated immune response (refs. 13,15). It has been demonstrated that the FI-RSV vaccine induced a TH2-type immune response in mice whereas immunization with live RSV, which does not cause immunopotentiation, elicits a TH1 response In some studies, the immune response to immunization with a synthetic RSV FG fusion protein resulted in disease enhancement in rodents resembling that induced by a formalin-inactivated RSV vaccine.
SUBSTITUTE SHEET (RULE 26) WO 99/04010 PCT/CA98/00697 4 Immunization of mice with a recombinant vaccinia virus expressing the RSV G protein resulted in G-specific
T
cell responses in the lungs which are exclusively recruited from the CD4+T cell sublineage and are strongly Th2-biased. G-specific T cells induce lung haemmorrage, pulmonary neutrophil recruitment (shock lung), intense pulmonary eosinophilia, and sometimes death in the adoptively transferred murine recipients (ref. 14). The association of immunization with disease enhancement using certain vaccine preparations including non-replicating antigens suggests caution in their use as vaccines in seronegative humans.
Live attenuated vaccines against disease caused by RSV may be promising for two main reasons. Firstly, infection by a live vaccine virus induces a balanced immune response comprising mucosal and serum antibodies and cytotoxic T-lymphocytes. Secondly, infection of infants with live attenuated vaccine candidates or naturally acquired wild-type virus is not associated with enhanced disease upon subsequent natural reinfection. It will be challenging to produce live attenuated vaccines that are immunogenic for younger infants who possess maternal virus-neutralizing antibodies and yet are attenuated for seronegative infants greater than or equal to 6 months of age.
Attenuated live virus vaccines also have the risks of residual virulence and genetic instability.
Injection of plasmid DNA containing sequences encoding a foreign protein has been shown to result in expression of the foreign protein and the induction of antibody and cytotoxic T-lymphocyte (CTL) responses to the antigen in a number of studies (see, for example, refs. 16, 17, 18). The use of plasmid DNA inoculation to express viral proteins for the purpose of immunization may offer several advantages over the SUBSTITUTE SHEET (RULE 26) WO 99/04010 PCT/CA98/00697 strategies summarized above. Firstly, DNA encoding a viral antigen can be introduced in the presence of antibody to the virus itself, without loss of potency due to neutralization of virus by the antibodies.
Secondly, the antigen expressed in vivo should exhibit a native conformation and the appropriate glycosylation.
Therefore, the antigen should induce an antibody response similar to that induced by the antigen present in the wild-type virus infection. In contrast, some processes used in purification of proteins can induce conformational changes which may result in the loss of immunogenicity of protective epitopes and possibly immunopotentiation. Thirdly, the expression of proteins from injected plasmid DNAs can be detected in vivo for a considerably longer period of time than that in virusinfected cells, and this has the theoretical advantage of prolonged cytotoxic T-cell induction and enhanced antibody responses. Fourthly, in vivo expression of antigen may provide protection without the need for an extrinsic adjuvant.
The ability to immunize against disease caused by RSV by administration of a DNA molecule encoding an RSV G protein was unknown before the present invention. In particular, the efficacy of immunization against
RSV
induced disease using a gene encoding a secreted form of the RSV G protein was unknown. Infection with RSV leads to serious disease. It would be useful and desirable to provide isolated genes encoding RSV G protein and nonreplicating vectors, including plasmid vectors, for in vivo administration and for use in immunogenic preparations, including vaccines, for protection against disease caused by RSV and for the generation of diagnostic reagents and kits. In particular, it would be desirable to provide vaccines that are immunogenic and protective in humans, including seronegative SUBSTITUTE SHEET (RULE 26)
S
6 infants, that do not cause disease enhancement (immunopotentiation).
SUMMARY OF THE INVENTION The present invention relates to a method of immunizing a host against disease caused by respiratory syncytial virus, to non-replicating vectors containing nucleic acid molecules used in immunogenic compositions for such purpose, and to diagnostic procedures utilizing the vectors and nucleic acid molecules. In particular, the present invention is directed towards the provision of nucleic acid vaccines encoding the G protein of respiratory syncytial virus.
In accordance with one aspect of the invention, there is provided and immunogenic composition for in vivo administration to a host for the generation in the host of protective antibodies to respiratory syncytial virus (RSV) G protein, comprising a plasmid vector comprising: a first nucleotide sequence encoding a RSV G protein or a RSV G protein fragment that generates antibodies that specifically react with RSV G protein, a promoter sequence operatively coupled to said first nucleotide sequence for expression of said RSV G protein in the host, and a second nucleotide sequence located between said first nucleotide sequence and said promoter sequence to increase expression of said RSV G protein in vivo from said vector in the host, and a pharmaceutically-acceptable carrier therefor, and wherein said immunogenic composition produces a balanced Thl/Th2 cytokine profile.
The first nucleotide sequence may be that which encodes a full-length RSV G protein. The first nucleotide sequence may comprise the nucleotide sequence shown in Figure 2 (SEQ ID NO: 1) or encode a full length RSV G protein having the amino acid sequence shown in Figure 2 (SEQ ID NO: 2).
WAV:olet\Nige607657\6 7 857_pg6.doc WO 99/04010 PCT/CA98/00697 7 Alternatively, the first nucleotide sequence may be that which encodes an RSV G protein from which the transmembrane coding sequence and sequences upstream thereof are absent. The first nucleotide sequence encoding the truncated RSV G protein may comprise the nucleotide sequence shown in Figure 3 (SEQ. ID no: 3) or may comprise a nucleotide sequence encoding the truncated RSV G protein having the amino acid sequence shown in Figure 3 (SEQ ID no: The lack of expression of the transmembrane region results in a secreted form of the RSV G protein.
The non-replicating vector may further comprise a heterologous signal peptide encoding nucleotide sequence immediately upstream of the 5'-terminus of the first nucleotide sequence. The signal peptide encoding sequence may encode the signal peptide of human tissue plasminogen activator.
The promoter sequence may be an immediate early cytomegalovirus (CMV) promoter. The second nucleotide sequence may comprise the human cytomegalovirus Intron
A.
The non-replicating vector generally is a plasmid vector. Plasmid vectors encoding the G protein and included in the immunogenic composition provided by this aspect of the invention may specifically be pXL5 or pXL6, constructed and having their characterizing elements, as seen in Figures 4 or 5, respectively.
In accordance with a further aspect of the present invention, there is provided a method of immunizing a host against disease caused by infection with respiratory syncytial virus (RSV), which comprises administering to the host an effective amount of a nonreplicating vector comprising: a first nucleotide sequence encoding an RSV G protein or a RSV G protein fragment that generates SUBSTITUTE SHEET (RULE 26) WO 99/04010 PCT/CA98/00697 8 antibodies that specifically react with RSV G protein, a promoter sequence operatively coupled to said first nucleotide sequence for expression of said RSV G protein in the host, and a second nucleotide sequence located between said first nucleotide sequence and said promoter sequence to increase expression of said RSV G protein in vivo from said vector in the host.
The immunization method may be effected to induce a balanced Thl/Th2 immune response.
The present invention also includes a novel method of using a gene encoding respiratory syncytial virus (RSV) G protein or a RSV G protein fragment that generates antibodies that specifically react with RSV G protein, to protect a host against disease caused by infection with respiratory syncytial virus, which comprises: isolating the gene; operatively linking the gene to at least one control sequence to produce a non-replicating vector, said control sequence directing expression of the RSV G protein when said vector is introduced into a host to produce an immune response to the RSV G protein, and introducing the vector into the host.
The procedure provided in accordance with this aspect of the invention may further include the step of: operatively linking the gene to an immunoprotection enhancing sequence to produce an enhanced immunoprotection by the RSV G protein in the host, preferably by introducing the immunoprotection enhancing sequence between the control sequence and the gene, including introducing immunostimulatory CpG sequences in the vector.
In addition, the present invention includes a method of producing a vaccine for protection of a host SUBSTITUTE SHEET (RULE 26) 9 against disease caused by infection with respiratory syncytial virus (RSV), which comprises: isolating a first nucleotide sequence encoding an RSV G protein. or a RSV G protein fragment that generates antibodies that specifically react with RSV G protein, operatively linking the first nucleotide sequence to at least one control sequence to produce a non-replicating vector, the control sequence directing expression of the RSV G protein when introduced into a host to produce an immune response to the RSV G protein when expressed in vivo from the vector in a host, operatively linking the first nucleotide sequence to a second nucleotide sequence to increase expression of the RSV G protein in vivo from the vector in a host, and a formulating the vector as a vaccine for in vivo e .administration.
The vector may be a plasmid vector selected from and pXL6. The invention further includes a vaccine for administration to a host, including a human host, produced 20 by this method.
The present invention provides a plasmid vector when i used as a medicament for immunizing a host against disease caused by infection with respiratory syncytial virus (RSV), said vector including: 25 a first nucleotide sequence encoding a RSV G protein or a RSV G protein fragment that generates antibodies that specifically react with RSV G protein, and a promoter sequence operatively coupled to said first nucleotide sequence for expression of said RSV G protein in the host; and a second nucleotide sequence located between said first nucleotide sequence and said promoter sequence to increase expression of said RSV G protein in vivo from said vector in the host; u and wherein said medicament produces a balanced UThl/Th2 cytokine profile ,4 W:\VWet\NIel\607857\607857_ 9.doc WO 99/04010 PCT/CA98/00697 RSV G protein in the host and a second nucleotide sequence located between the first nucleotide sequence and the promoter sequence to increase expression of the RSV G protein in vivo from the vector in the host; isolating the RSV G protein-specific antibodies; contacting the sample with the isolated antibodies to produce complexes comprising any RSV G protein present in the sample and the RSV G protein-specific antibodies; and determining production of the complexes.
The non-replicating vector employed to elicit the antibodies may be a plasmid vector pXL5 or pXL6.
The invention also includes a diagnostic kit for detecting the presence of a respiratory syncytial virus (RSV) G protein in a sample, comprising: a non-replicating vector capable of generating antibodies specific for the RSV G protein when administered to a host, said nonreplicating vector comprises a first nucleotide sequence encoding an RSV G protein or an RSV G protein fragment that generates antibodies that specifically react with RSV G protein, a promoter sequence operatively coupled to the first nucleotide sequence for expression of the RSV G protein in a host, and a second nucleotide sequence located between the first nucleotide sequence and the promoter sequence to increase expression of the RSV G protein in vivo from the vector in the host; isolation means to isolate the RSV G protein specific antibodies; contacting means to contact the isolated RSV G protein-specific antibodies with the sample to produce a complex comprising any RSV G protein SUBSTITUTE SHEET (RULE 26) WO 99/04010 PCT/CA98/00697 11 present in the sample and RSV G protein specific antibodies; and identifying means to determine production of the complex.
The present invention further is directed to a method for producing antibodies specific for a G protein of a respiratory syncytial virus (RSV) comprising: immunizing a host with an effective amount of a non-replicating vector to produce RSV G-specific antibodies, said non-replicating vector comprising: a first nucleotide sequence encoding a RSV G protein or a RSV G protein fragment that generates antibodies that specifically react with RSV G protein, a promoter sequence operatively coupled to said first nucleotide sequence for expression of said RSV G protein in the host, and a second nucleotide sequence located between said first nucleotide sequence and said promoter sequence to increase expression of said RSV G protein in vivo from said vector in the host; and isolating the RSV G specific antibodies from the host.
The present invention is also directed to a method for producing monoclonal antibodies specific for a G protein of respiratory syncytial virus (RSV), comprising the steps of: constructing a vector comprising a first nucleotide sequence encoding a RSV G protein or a RSV G protein fragment that generates antibodies that specifically react with RSV G protein, a promoter sequence operatively coupled to the first nucleotide sequence for expression of the RSV G protein in the host and a second nucleotide SUBSTITUTE SHEET (RULE 26) WO 99/04010 PCT/CA98/00697 12 sequence located between the first nucleotide sequence and the promoter sequence to increase expression of the RSV G protein when in vivo from the vector in a host; administering the vector to at least one mouse to produce at least one immunized mouse; removing B-lymphocytes from the at least one immunized mouse; fusing the B-lymphocytes from the at least one immunized mouse with myeloma cells, thereby producing hybridomas; cloning the hybridomas; selecting clones which produce anti-RSV G protein antibody; culturing the anti-RSV G protein antibodyproducing clones; and isolating anti-RSV G protein monoclonal antibodies.
Such monoclonal antibodies may be used to purify RSV G protein from virus.
In this application, the term "RSV G protein" is used to define a full-length RSV G protein, such proteins having variations in their amino acid sequences including those naturally occurring in various strains of RSV, a secreted form of RSV G protein lacking a transmembrane region, as well as functional analogs of the RSV G protein. In this application, a first protein is a "functional analog" of a second protein if the first protein is immunologically related to and/or has the same function as the second protein. The functional analog may be, for example, an immunologically-active fragment of the protein or an immunologically-active substitution, addition or deletion mutant thereof.
SUBSTITUTE SHEET (RULE 26) WO 99/04010 PCT/CA98/00697 13 BRIEF DESCRIPTION OF THE FIGURES The present invention will be further understood from the following General Description and Examples with reference to the Figures of the accompanying drawings, in which: Figure 1 illustrates a restriction map of the gene encoding a G protein of respiratory syncytial virus
(RSV);
Figure 2 illustrates the nucleotide sequence of a gene encoding a membrane bound form of the G protein of respiratory syncytial virus (SEQ ID No: 1) as well as the amino acid sequence of the RSV G protein encoded thereby (SEQ ID No: 2); Figure 3 illustrates the nucleotide sequence of a gene encoding the secreted form of the RSV G protein lacking the transmembrane domain (SEQ ID No: 3) as well as the amino acid sequence of a truncated RSV G protein lacking the transmembrane domain encoded thereby (SEQ ID No: 4); Figure 4 shows the construction of plasmid containing a gene encoding a full-length membrane attached form of the RSV G protein and containing the CMV Intron A sequence; Figure 5 shows the construction of plasmid pXL6 containing a gene encoding a secreted form of the RSV G protein lacking the transmembrane domain and containing the CMV Intron A sequence as well as a nucleotide sequence encoding a signal peptide of the human tissue plasminogen activator (TPA); Figure 6 shows the nucleotide sequence for the plasmid VR-1012 (SEQ ID No. Figure 7 shows the nucleotide sequence for the untranslated region and the signal peptide of the human tissue plasminogen activator (TPA)(SEQ. ID no: 6) and Figure 8 shows the lung cytokine expression profile SUBSTITUTE SHEET (RULE 26) WO 99/04010 PCT/CA98/00697 14 in DNA immunized mice after RSV challenge.
GENERAL DESCRIPTION OF INVENTION As described above, the present invention relates generally to polynucleotide, including DNA, immunization to obtain protection against infection by respiratory syncytial virus (RSV) and to diagnostic procedures using particular non-replicating vectors. In the present invention, several recombinant plasmid vectors were constructed to contain a nucleotide sequence encoding an RSV G protein.
The nucleotide sequence of the full length RSV G gene is shown in Figure 2 (SEQ ID No: Certain constructs provided herein include the nucleotide sequence encoding the full-length RSV G (SEQ ID No: 2) protein while others include an RSV G gene modified by deletion of the transmembrane coding sequence and nucleotides upstream thereof (see Figure 3, SEQ ID No: to produce a secreted or truncated RSV G protein lacking the transmembrane domain (SEQ ID No. 4).
The nucleotide sequence encoding the RSV G protein is operatively coupled to a promoter sequence for expression of the encoded RSV G protein in vivo. The promoter sequence may be the human immediately early cytomegalovirus (CMV) promoter. This promoter is described in ref. 19. Any other convenient promoter may be used, including constitutive promoters, such as, the Rous Sarcoma Virus LTRs, and inducible promoters, such as the metallothionin promoter, and tissue specific promoters.
The non-replicating vectors provided herein, when administered to an animal in the form of an immunogenic composition with a pharmaceutically-acceptable carrier, effect in vivo RSV G protein expression, as demonstrated by an antibody response in the animal to which it is administered. Such antibodies may be used herein in the SUBSTITUTE SHEET (RULE 26) WO 99/04010 PCT/CA98/00697 detection of RSV protein in a sample, as described in more detail below. The administration of the nonreplicating vectors, specifically plasmids pXL5 and pXL6, produced anti-G antibodies, virus neutralizing antibodies, a balanced Thl/Th2 response in the lungs post viral challenge and conferred protection in mice against live RSV infection, as seen from the Examples below.
The recombinant vector also may include a second nucleotide sequence located adjacent the RSV G protein encoding nucleotide sequence to enhance the immunoprotective ability of the RSV G protein when expressed in vivo in a host. Such enhancement may be provided by increased in vivo expression, for example, by increased mRNA stability, enhanced transcription and/or translation. This additional sequence generally is located between the promoter sequence and the RSV G protein-encoding sequence. This enhancement sequence may comprise the immediate early cytomegalovirus Intron A sequence.
The non-replicating vector provided herein may also comprise an additional nucleotide sequence encoding a further antigen from RSV, an antigen from at least one other pathogen or at least one immunomodulating agent, such as a cytokine. Such vector may contain the additional nucleotide sequence in a chimeric or a bicistronic structure. Alternatively, vectors containing the additional nucleotide sequence may be separately constructed and coadministered to a host, along with the non-replicating vectors provided herein.
The non-replicating vector may further comprise a nucleotide sequence encoding a heterologous viral or eukaryotic signal peptide, such as the human tissue plasminogen activator (TPA) signal peptide, in place of the endogenous signal peptide for the truncated RSV G SUBSTITUTE SHEET (RULE 26) WO 99/04010 PCT/CA98/00697 16 protein. Such nucleotide sequence may be located immediately upstream of the RSV G encoding sequence in the vector.
The immunogenicity of the non-replicating
DNA
vectors may be enhanced by inserting immunostimulatory CpG sequences in the vector.
It is clearly apparent to one skilled in the art, that the various embodiments of the present invention have many applications in the fields of vaccination, diagnosis and treatment of RSV infections. A further non-limiting discussion of such uses is further presented below.
1. Vaccine Preparation and Use Immunogenic compositions, suitable to be used as vaccines, may be prepared from the RSV G genes and vectors as disclosed herein. The vaccine elicits an immune response in an animal which includes the production of anti-RSV G antibodies. Immunogenic compositions, including vaccines, containing the nucleic acid may be prepared as injectables, in physiologicallyacceptable liquid solutions or emulsions for polynucleotide administration. The nucleic acid may be associated with liposomes, such as lecithin liposomes or other liposomes known in the art, as a nucleic acid liposome (for example, as described in WO 9324640, ref.
or the nucleic acid may be associated with an adjuvant, as described in more detail below. Liposomes comprising cationic lipids interact spontaneously and rapidly with polyanions, such as DNA and RNA, resulting in liposome/nucleic acid complexes that capture up to 100% of the polynucleotide. In addition, the polycationic complexes fuse with cell membranes, resulting in an intracellular delivery of polynucleotide that bypasses the degradative enzymes of the lysosomal compartment. Published PCT application WO 94/27435 SUBSTITUTE SHEET (RULE 26) WO 99/04010 PCT/CA98/00697 17 describes compositions for genetic immunization comprising cationic lipids and polynucleotides. Agents which assist in the cellular uptake of nucleic acid, such as calcium ions, viral proteins and other transfection facilitating agents, may advantageously be used.
Polynucleotide immunogenic preparations may also be formulated as microcapsules, including biodegradable time-release particles. Thus, U.S. Patent 5,151,264 describes a particulate carrier of a phospholipid/glycolipid/polysaccharide nature that has been termed Bio Vecteurs Supra Mol6culaires (BVSM). The particulate carriers are intended to transport a variety of molecules having biological activity in one of the layers thereof.
U.S. Patent 5,075,109 describes encapsulation of the antigens trinitrophenylated keyhole limpet hemocyanin and staphylococcal enterotoxin B in 50:50 poly (DL-lactideco-glycolide). Other polymers for encapsulation are suggested, such as poly(glycolide), poly(DL-lactide-co- glycolide), copolyoxalates, polycaprolactone, poly(lactide-co-caprolactone), poly(esteramides), polyorthoesters and poly(8hydroxybutyric acid), and polyanhydrides.
Published PCT application WO 91/06282 describes a delivery vehicle comprising a plurality of bioadhesive microspheres and antigens. The microspheres being of starch, gelatin, dextran, collagen or albumin. This delivery vehicle is particularly intended for the uptake of vaccine across the nasal mucosae. The delivery vehicle may additionally contain an absorption enhancer.
The RSV G gene containing non-replicating vectors may be mixed with pharmaceutically acceptable excipients which are compatible therewith. Such excipients may include, water, saline, dextrose, glycerol, ethanol, and SUBSTITUTE SHEET (RULE 26) WO 99/04010 PCT/CA98/00697 18 combinations thereof. The immunogenic compositions and vaccines may further contain auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, or adjuvants to enhance the effectiveness thereof.
Immunogenic compositions and vaccines may be administered parenterally, by injection subcutaneously, intravenously, intradermally or intramuscularly, possibly following pretreatment of the injection site with a local anesthetic. Alternatively, the immunogenic compositions formed according to the present invention, may be formulated and delivered in a manner to evoke an immune response at mucosal surfaces. Thus, the immunogenic composition may be administered to mucosal surfaces by, for example, the nasal or oral (intragastric) routes. Alternatively, other modes of administration including suppositories and oral formulations may be desirable. For suppositories, binders and carriers may include, for example, polyalkylene glycols or triglycerides. Oral formulations may include normally employed incipients, such as, for example, pharmaceutical grades of saccharine, cellulose and magnesium carbonate.
The immunogenic preparations and vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective, protective and immunogenic.
The quantity to be administered depends on the subject to be treated, including, for example, the capacity of the individual's immune system to synthesize the RSV G protein and antibodies thereto, and if needed, to produce a cell-mediated immune response. Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner. However, suitable dosage ranges are readily determinable by one skilled in the art and may be of the order of about 1 jg SUBSTITUTE SHEET (RULE 26) WO 99/04010 PCT/CA98/00697 19 to about 2 mg of the RSV G gene-containing vectors.
Suitable regimes for initial administration and booster doses are also variable, but may include an initial administration followed by subsequent administrations.
The dosage may also depend on the route of administration and will vary according to the size of the host. A vaccine which protects against only one pathogen is a monovalent vaccine. Vaccines which contain antigenic material of several pathogens are combined vaccines and also belong to the present invention. Such combined vaccines contain, for example, material from various pathogens or from various strains of the same pathogen, or from combinations of various pathogens.
Immunogenicity can be significantly improved if the vectors are co-administered with adjuvants, commonly used as 0.05 to 0.2 percent solution in phosphatebuffered saline. Adjuvants enhance the immunogenicity of an antigen but are not necessarily immunogenic themselves. Adjuvants may act by retaining the antigen locally near the site of administration to produce a depot effect facilitating a slow, sustained release of antigen to cells of the immune system. Adjuvants can also attract cells of the immune system to an antigen depot and stimulate such cells to elicit immune responses.
Immunostimulatory agents or adjuvants have been used for many years to improve the host immune responses to, for example, vaccines. Thus, adjuvants have been identified that enhance the immune response to antigens.
Some of these adjuvants are toxic, however, and can cause undesirable side-effects, making them unsuitable for use in humans and many animals. Indeed, only aluminum hydroxide and aluminum phosphate (collectively commonly referred to as alum) are routinely used as SUBSTITUTE SHEET (RULE 26) WO 99/04010 PCT/CA98/00697 adjuvants in human and veterinary vaccines.
A wide range of extrinsic adjuvants and other immunomodulating material can provoke potent immune responses to antigens. These include saponins complexed to membrane protein antigens to produce immune stimulating complexes (ISCOMS), pluronic polymers with mineral oil, killed mycobacteria in mineral oil, Freund's complete adjuvant, bacterial products, such as muramyl dipeptide (MDP) and lipopolysaccharide (LPS), as well as monophoryl lipid A, QS 21 and polyphosphazene.
In particular embodiments of the present invention, the non-replicating vector comprising a first nucleotide sequence encoding an G protein of RSV may be delivered in conjunction with a targeting molecule to target the vector to selected cells including cells of the immune system.
The immunogenicity of the non-replicating vector may be enhanced by coadministering plasmid DNA vectors expressing cytokines or chemokines or by coexpressing such molecules in a bis-cistronic or fusion construct.
The non-replicating vector may be delivered to the host by a variety of procedures, for example, Tang et al. (ref. 21) disclosed that introduction of gold microprojectiles coated with DNA encoding bovine growth hormone (BGH) into the skin of mice resulted in production of anti-BGH antibodies in the mice, while Furth et al. (ref. 22) showed that a jet injector could be used to transfect skin, muscle, fat and mammary tissues of living animals.
2. Immunoassays The RSV G genes and vectors of the present invention are useful as immunogens for the generation of anti-G antibodies for use in immunoassays, including enzyme-linked immunosorbent assays (ELISA), RIAs and other non-enzyme linked antibody binding assays or SUBSTITUTE SHEET (RULE 26) WO 99/04010 PCT/CA98/00697 21 procedures known in the art. In ELISA assays, the nonreplicating vector first is administered to a host to generate antibodies specific to the RSV G protein.
These RSV G-specific antibodies are immobilized onto a selected surface, for example, a surface capable of binding the antibodies, such as the wells of a polystyrene microtiter plate. After washing to remove unadsorbed antibodies, a non-specific protein, such as a solution of bovine serum albumin (BSA) that is known to be antigenically neutral with regard to the test sample, may be bound to the selected surface. This allows for blocking of non-specific adsorption sites on the immobilizing surface and thus reduces the background caused by nonspecific bindings of antisera onto the surface.
The immobilizing surface is then contacted with a sample, such as clinical or biological materials, to be tested in a manner conducive to immune complex (antigen/antibody) formation. This procedure may include diluting the sample with diluents, such as solutions of BSA, bovine gamma globulin (BGG) and/or phosphate buffered saline (PBS)/Tween. The sample is then allowed to incubate for from about 2 to 4 hours, at temperatures such as of the order of about 200 to 37 0
C.
Following incubation, the sample-contacted surface is washed to remove non-immunocomplexed material. The washing procedure may include washing with a solution, such as PBS/Tween or a borate buffer. Following formation of specific immunocomplexes between the test sample and the bound RSV G specific antibodies, and subsequent washing, the occurrence, and even amount, of immunocomplex formation may be determined.
BIOLOGICAL MATERIALS Certain plasmids that contain the gene encoding the RSV G protein and referred to herein have been deposited SUBSTITUTE SHEET (RULE 26) WO 99/04010 PCT/CA98/00697 22 with the American Type Culture Collection (ATCC) located at 12301 Parklawn Drive, Rockville, Maryland, 20852, pursuant to the Budapest Treaty and prior to the filing of this application.
Samples of the deposited plasmids will become available to the public upon grant of a patent based upon this United States patent application and all restrictions on access to the deposits will be removed at that time. Samples of the deposited plasmids will be replaced if the depository is unable to dispense viable samples. The invention described and claimed herein is not to be limited in scope by plasmids deposited, since the deposited embodiment is intended only as an illustration of the invention. Any equivalent or similar plasmids that encode similar or equivalent antigens as described in this application are within the scope of the invention.
Plasmid ATCC DesiQnation Date Deposited 209143 July 16, 1997 pXL6 209144 July 16, 1997
EXAMPLES
The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific Examples. These Examples are described solely for purposes of illustration and are not intended to limit the scope of the invention. Changes in form and substitution of equivalents are contemplated as circumstances may suggest or render expedient. Although specific terms have been employed herein, such terms are intended in a descriptive sense and not for purposes of limitations.
Methods of molecular genetics, protein biochemistry, and immunology used but not explicitly described in this disclosure and these Examples are SUBSTITUTE SHEET (RULE 26) WO 99/04010 PCT/CA98/00697 23 amply reported in the scientific literature and are well within the ability of those skilled in the art.
Example 1 This Example describes the construction of vectors containing the RSV G gene.
Figure 1 shows a restriction map of the gene encoding the G protein of respiratory syncytial virus and Figure 2 shows the nucleotide sequence of the gene encoding the full-length RSV G protein (SEQ ID No: 1) and the deduced amino acid sequence (SEQ ID No: 2).
Figure 3 shows the gene encoding the secreted RSV G protein (SEQ ID No: 3) and the deduced amino acid sequence (SEQ ID No: 4).
Plasmid pXL5 (Figure 4) was prepared for the expression of the full-length RSV G protein as follows: A recombinant Bluescript plasmid (RSV G12) containing the cDNA encoding the full-length G protein of a clinical RSV isolate (subgroup A) was used to construct vectors for RSV DNA-G immunization. RSV G12 was digested with AflIII and EcoRI and filled-in with the Klenow subunit of DNA polymerase. The resulting 1.23 kb fragment containing the coding sequence for the full-length G protein was gel-purified and ligated to VR-1012 (Vical) (Figure 6) previously linearized with EcoRV. This procedure placed the RSV G cDNA downstream of the immediate-early cytomegalovirus (CMV) promoter and Intron A sequences of human cytomegalovirus
(CMV)
and upstream of the bovine growth hormone (BGH) poly-A site. The junctions of the cDNA fragments in the plasmid construct were confirmed by sequencing analysis. The resulting plasmid was designated Plasmid pXL6 (Figure 5) was prepared for the expression of a secretory RSV G protein as follows: RSV G12 was digested with EcoRI, filled-in with Klenow and digested again with BamHI. The BamHI SUBSTITUTE SHEET (RULE 26) WO 99/04010 PCT/CA98/00697 24 cleavage resulted in the generation of a cDNA fragment encoding a RSV G protein with N-terminal truncation.
This DNA segment was gel-purified and ligated in the presence of a pair of 11 mer oligodeoxynucleotides (5'GATCCACTCAG (SEQ ID no: 7) 3' GTGAGTCCTAG 5' (SEQ ID no: 8) to VR-1020 (Vical) previously digested with BglII, filled in with Klenow, digested again with BamHI and gel-purified. This procedure placed the truncated RSV G cDNA (lacking the coding region for the N-terminal 91 amino acid residues including the transmembrane domain) downstream of the immediate-early CMV promoter and Intron A sequences of human CMV and upstream of the BGH poly-A site. In addition, there was the introduction of approximately 100 bp of 5' untranslated region and the coding sequence for the signal peptide of human plasminogen activator protein (Figure 7) fused in frame to the N-terminus of the RSV G protein coding sequence downstream of the CMV promoter/Intron A sequences. The junctions of the cDNA fragments in the plasmid construct were confirmed by sequencing analysis. The resulting plasmid was designated pXL6.
Example 2 This Example describes the immunization of mice.
Mice are susceptible to infection by RSV as described in ref. 24.
Plasmid DNA was purified through double CsCl centrifugations. For intramuscular immunization, tibialis anterior muscles of BALB/c mice (male, 6 to 8 week old) (Jackson Lab., Bar Harbor, ME, USA) were bilaterally injected with 2 x 50|tg (l1g/L in PBS) of either pXL5, pXL6 or V-1012. Five days prior to DNA injection, the muscles were treated with 2 x 50ptL in PBS) of cardiotoxin (Latoxan, France) to increase DNA uptake and enhance immune responses, as reported by SUBSTITUTE SHEET (RULE 26) WO 99/04010 PCT/CA98/00697 Davis et al (ref. 23). The animals were boosted with the same dose of plasmid DNA 6 weeks and 13 weeks later, respectively. For intradermal immunization, 100pg of the plasmid DNA (2pg/RL in PBS) of were injected at the base of the tail and boosted 6 weeks and 13 weeks later, respectively. Mice in the positive control group were immunized intranasally with 106 plaque forming units (pfu) of a clinical RSV strain of the A2 subtype grown in Hep2 cells kindly provided by Dr. B. Graham (ref. 24).
Four weeks after the third immunization, mice were challenged intranasally with 106 pfu of the RSV A2 strain. Lungs were asceptically removed 4 days later, weighed and homogenized in 2 mL of complete culture medium (ref. 25). The number of pfu in lung homogenates was determined in duplicate as previously described (ref. 26) using vaccine-quality Vero cells.
Example 3 This Example describes the immunogenicity and protection by polynucleotide immunization.
Antisera obtained from immunized mice were analyzed for anti-RSV G IgG antibody titres using specific enzyme-linked immunosorbent assay (ELISA) and for RSVspecific plaque-reduction titres. ELISAs were performed using 96-well plates coated with immunoaffinity-purified RSV G protein (50 ng/mL)and 2-fold serial dilutions of immune sera. A goat anti-mouse IgG antibody conjugated to alkaline phosphatase (Jackson ImmunoRes., Mississauga, Ontario, Canada) was used as secondary antibody. Plaque reduction titres were determined according to Prince et al (ref. 26) using vaccinequality Vero cells. Four-fold serial dilutions of immune sera were incubated with 50 pfu of the RSV Long strain (ATCC) in culture medium at 37 0 C for 1 hr in the presence of 5% CO 2 and the mixtures were used to infect SUBSTITUTE SHEET (RULE 26) WO 99/04010 PCT/CA98/00697 26 Vero cells. Plaques were fixed with 80% methanol and developed 5 days later using a mouse anti-RSV F monoclonal IgG1 antibody and donkey anti-mouse IgG antibody conjugated to peroxidase (Jackson ImmunoRes., Mississauga, Ontario, Canada). The RSV-specific plaque reduction titre was defined as the dilution of serum sample yielding 60% reduction in plaque number. Both ELISA and plaque reduction assays were performed in duplicate and data are expressed as the means of two determinations.
The results obtained are reproduced in Tables I and II below: SUBSTITUTE SHEET (RULE 26) WO 99/04010 WO 9904010PCT/CA98/00697 27 Table L Immunogenicity of DNA-G inBA.LBIcMce Immunogen Anti-PS VG JgG Titre RSV-Specific (Log 2(titre/100) Plaque Reduction Titre 6 weeks 10 weeks 17 weeks (Log 2 titre) 17 weeks VR- 10 12 0.00 +0.00 0.00 +0.00 0.00 +0.00 0.00 +0.00 3.10+2.77 9.70+ 1.06 8.60+ 1.17 5.40+ 1.65 pXL6 5.78 +1.20 9.30 +0.82 8.89 +1.54 7.26 +0.82 pXLS 1.50+1.27 8.60+ 1.43 8.30+ 1.25 7.92+0.59 pXL6 3.70±+1.25 10.30 +1.06 9.44 +1.24 6.92 +0.94 RSV 6.83 +0.41 9.67+0.52 9.83 +0.41 11.80+0.08 SUBSTITUTE SHEET (RULE 26) WO 99/04010 WO 9904010PCT/CA98/00697 28 TablefIL immunoprotective Ablty oN- Gin BALB/c Mice Immunogen No. Mice Mean Vrus Lung Ttre ('pfu/g Jung) (Log 10±+ SD) No. Fully Protected Mice# VR-1012 (i.xn.) pXL6 pXL6 RSV 4.81 +0.01 0.29 0.90 0.40 1.20 0.30 1.10 0.29 0.90 0.00 +0.00 *Senitivity of the assay: 101.9 pfi/g lung.
The term, fully protected mice, refers to animals with no detectable RSV in the lungs 4 days post viral challenge.
SUBSTITUTE SHEET (RULE 26) WO 99/04010 PCT/CA98/00697 29 As seen in Table I, plasmids pXL5 and pXL6 were found to be immunogenic following either i.m. or i.d.
immunization producing anti-G antibodies and virus neutralizing antibodies. In addition, as seen in Table II, the plasmids pXL5 and pXL6 protected immunized mice against primary RSV infection of the lower respiratory tract. The control vector produced no immune response and did not confer protection.
Example 4 This Example describes the determination of the local lung cytokine expression profile in mice immunized with pXL5 and pXL6 after RSV challenge.
BALB/c mice were immunized at 0 and 6 weeks with 100lg of pXL5 and 6, prepared as described in Example 1, and challenged with RSV i.n. at 10 weeks. Control animals were immunized with placebo PI-RSV and live RSV and challenged with RSV according to the same protocol.
In addition, animals were immunized with pXL2, as described in copending United States Patent Application no. 08/476,397 filed June 7, 1995 (WO 96/40945) and challenged with RSV, also following the same protocol.
Four days post viral challenge, lungs were removed from immunized mice and immediately frozen in liquid nitrogen. Total RNA was prepared from lungs homogenized in TRIzol/p-mercaptoethanol by chloroform extraction and isopropanol precipitation. Reverse transcriptasepolymerase chain reaction (RT-PCR) was then carried out on the RNA samples using either IL-4, IL-5 or IFN-y specific primers from CloneTech. The amplified products were then liquid-hybridized to cytokine-specific 32
P-
labeled probes from CloneTech, resolved on polyacrylamide gels and quantitated by scanning of the radioactive signals in the gels. Three mouse lungs were removed from each treatment group and analyzed for lung cytokine expression for a minimum of two times. The SUBSTITUTE SHEET (RULE 26) WO 99/04010 PCT/CA98/00697 data is presented in Figure 8 and represents the means and standard deviations of these determinations.
As may be seen from the data presented in Figure 8: 1. Immunization with live RSV intranasally resulted in a balanced cytokine profile (IFN-y, IL- 4 and IL-5), whereas that with FI-RSV intramuscularly resulted in a Th2 predominance (elevated IL-4 and IL-5). These results are similar to those reported in the literature.
2. Immunization with pXL5 or pXL6 via either the i.m. or intradermal route gave rise to a balanced cytokine profile similar to that with live RSV immunization.
3. The magnitude of the cytokine responses with i.m. pXL6 (RSV G) and pXL2 (RSV F) immunization using the construct expressing a secretory form of the protein (SEC) is significantly higher than that with live RSV immunization.
4. The magnitude of the cytokine response with immunization using constructs expressing a full-length membrane-associated RSV G protein (MA) and i.d. pXL6 was somewhat higher than that with live RSV immunization.
The balanced local cytokine response observed with DNA-G immunization contrasts with that reported by Openshaw et al (ref. 13). Using a recombinant vaccinia virus expressing the G protein, these investigators reported a local Th2 response by analysis of bronchoalveolar lavage.
The results herein, which were obtained through a monogenic approach, indicate that the Th2 response is not necessarily an intrinsic property of the G protein.
SUBSTITUTE SHEET (RULE 26) WO 99/04010 PCT/CA98/00697 31 SUMMARY OF THE DISCLOSURE In summary of this disclosure, the present invention provides certain novel non-replicating vectors containing genes encoding RSV G proteins, methods of immunization using such vectors and methods of diagnosis using such vectors. Modifications are possible within the scope of this invention.
SUBSTITUTE SHEET (RULE 26) WO 99/04010 PCT/CA98/00697 32
REFERENCES
1. McIntosh Canock, R.M. In: Fields B.N, Knipe, DM, editors. Virology. New York: Raven Press: 1990: 1045-1072 2. Heilman, J. Infect. Dis. 1990, 161: 402 to 406.
3. Wertz GW, Sullender WM., Biotechnology 1992; 151-176 4. Murphy, B. R. et al, 1994, Virus Res. 32: 13-36.
Levine, Kleiber-France, and Paradiso, P.R.
(1987) J. Gen. Virol. 69, 2521-2524.
6. Anderson, Hierholzer, Tsou, Hendry, Fernie, Stone, Y. and McIntosh, K.
(1985) J. Infect. Dis. 151, 626-633.
7. Johnson et al., J. Virol 1987, 61: 3163-3166 8. Crowe, Vaccine 1995, 13: 415-421 9. Kapikian, A.Z. et al 1969, Am. J. Epidemiol. 89: 405-421.
Kim, et al 1969 Am. J. Epidemiol. 89: 422- 434.
11. Murphy, B.R. et al 1986 J. Clin. Microbiol. 24: 197-202.
12. Vaux-Peretz, F. et al 1992 Vaccine 10: 113-118.
13. Openshaw, P.J. 1995 Springer-Semin Immunopathol.
17: 187-201.
14. Alwan et al 1994 J. Exp. Med. 179:81-89.
Graham, B.S. 1995 Am. J. Respir. Crit. Care Med.
152:563-6 16. WO 90/11092 17. WO 94/21797 18. Ulmer, Current Opinion, Invest Drugs, 1993, 2: 983- 989 19. Chapman, Thayer, Vincent, K.A. and Haigwood, Nucl. Acids. Res. 1991, 19: 3979- 3986.
SUBSTITUTE SHEET (RULE 26) WO 99/04010 PCT/CA98/00697 33 Nabel, G.J. 1993, Proc. Natl. Acad. Sci. USA 11307-11311.
21. Tang et al., Nature 1992, 356: 152-154 22. Furth et al. Analytical Biochemistry, 1992, 205: 365-368 23. Davis et al., Vaccine 1994, 12: 1503-1509 24. Graham, Perkins Wright, P.F. and Karzon, D.T. J. Mod. Virol. 1988 26: 153-162.
Du, R.P et al. 1994., Bio Technology 12: 813-818.
26. Prince, G.A. et al, 1978. Ame. J. Pathol. 93: 771- 790.
SUBSTITUTE SHEET (RULE 26)
Claims (23)
1. An immunogenic composition for in vivo administration to a host for the generation in the host of protective antibodies to respiratory syncytial virus (RSV) G protein, including: i. a plasmid vector including: a first nucleotide sequence encoding a RSV G protein or a RSV G protein fragment that generates antibodies that specifically react with RSV G protein, a promoter sequence operatively coupled to said first nucleotide sequence for expression of said RSV G protein in the host, and a second nucleotide sequence located between said first nucleotide sequence and said promoter sequence to increase expression of said RSV G protein in vivo from said vector in the host; and ii. a pharmaceutically-acceptable carrier therefore, 15 and wherein said immunogenic composition produces a balanced Thl/Th2 cytokine profile.
2. A composition as claimed in claim 1, in which said first nucleotide sequence encodes a full-length RSV G protein. S3. A composition as claimed in claim 2, in which said first nucleotide sequence comprises the nucleotide sequence shown in Figure 2 (SEQ ID NO: 1). .l
4. A composition as claimed in claim 2, in which said first nucleotide sequence comprises the nucleotide encoding a full length RSV G protein having the amino acid sequence shown in Figure 2 (SEQ ID NO:2). A composition as claimed in claim 1, in which said first nucleotide sequence encodes a RSV G protein from which the transmembrane coding sequence and sequences upstream thereto are absent.
6. A composition as claimed in claim 5, in which said first nucleotide sequence comprises the nucleotide sequence shown in Figure 3 (SEQ ID NO: 3) w:wViole~Nigel60785707857_icaims.doc
7. A composition as claimed in claim 5, in which said first nucleotide sequence comprises a nucleotide sequence encoding a truncated RSV G protein having the amino acid sequence shown in Figure 3 (SEQ ID NO: 4).
8. A composition as claimed in any one of claims 1 to 7, in which said vector further comprises a heterologous signal peptide encoding nucleotide sequence immediately upstream of the 5'-terminus of said first nucleotide sequence.
9. A composition as claimed in claim 8, in which said signal peptide encoding sequence encodes the signal peptide for human tissue plasminogen activator.
10. A composition as claimed in any one of claims 1 to 9, in which said promoter sequence is an immediate early cytomegalovirus promoter.
11. A composition as claimed in any one of claims 1 to 10, in which said second nucleotide sequence is the human cytomegalovirus Intron A.
12. A composition as claimed in any one of claims 1 to 11, in which the plasmid vector is pXL5 as shown in Figure 4.
13. A composition as claimed in any one of claims 1 to 11, in which the plasmid vector is pXL6 as shown in Figure
14. An immunogenic composition for in vivo administration to a host as claimed in claim 1 substantially as hereinbefore described with reference to the Examples. An immunogenic composition for in vivo administration to a host as claimed in claim 1 substantially as hereinbefore described with reference to and as illustrated in the accompanying drawings. wAioet\NigeM~ors787577daims.doC 36
16. A plasmid vector when used as a medicament for immunizing a host against disease caused by infection with respiratory syncytial virus RSV, said vector including: i. a first nucleotide sequence encoding a RSV G protein or a RSV G protein fragment that generates antibodies that specifically react with RSV G protein, and ii. a promoter sequence operatively coupled to said first nucleotide sequence for expression of said RSV G protein in the host; and iii. a second nucleotide sequence located between said first nucleotide sequence and said promoter sequence to increase expression of said RSV G protein in vivo form said vector in the host, and wherein said medicament produces a balanced Thl/Th2 cytokine profile. 9
17. A vector as claimed in claim 16, in which said first nucleotide sequence 15 encodes a full-length RSV G protein or encodes a RSV G protein from which the transmembrane coding sequence and sequences upstream thereto are 99 absent.
18. A vector as claimed in claim 17, in which said nucleotide sequence comprises the nucleotide sequence shown in Figure 2 (SEQ ID NO: 1) or encodes a full length RSV G protein shown in Figure 2 (SEQ ID NO: 2).
19. A vector as claimed in claim 17, in which said first nucleotide sequence comprises the nucleotide sequence shown in Figure 3 (SEQ ID NO: 3) or encodes a truncated RSV G protein having the same amino acid sequence shown in Figure 3 (SEQ ID NO: 4). A vector as claimed in any one of claims 16 to 19, in which said vector further comprises a heterologous signal peptide encoding nucleotide sequences immediately upstream of the 5'-terminus of said first nucleotide sequence.
21. A vector as claimed in claim 20, in which said signal peptide encoding sequence encodes the signal peptide for human tissue plasminogen activator. dalms.dc 37
22. A vector as claimed in any one of claims 16 to 21, in which said promoter sequence is an immediate early cytomegalovirus promoter.
23. A vector as claimed in any one of claims 16 to 22, in which said second nucleotide sequence is the human cytomegalovirus Intron A.
24. A vector as claimed in any one of claims 16 to 23, in which said plasmid vector is pXL5 as shown in Figure 4 or pXL6 as shown in Figure
25. A vector as claimed in claim 16 substantially as hereinbefore described with reference to the Examples.
26. A vector as claimed in claim 16 substantially as hereinbefore described with reference to and illustrated in the accompanying drawings.
27. A method of immunizing a host against a disease caused by RSV infection, "which includes in vivo administration to the host of a composition as claimed in any one of claims 1 to 15 for generation in the host of protective antibodies to RSV G protein and a balanced Thl/Th2 cytokine profile in the host. DATED: 15 November 2002 PHILLIPS ORMONDE FITZPATRICK Attorneys for: CONNAUGHT LABORATORIES LIMITED
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89644297A | 1997-07-18 | 1997-07-18 | |
| US08/896442 | 1997-07-18 | ||
| PCT/CA1998/000697 WO1999004010A1 (en) | 1997-07-18 | 1998-07-16 | Nucleic acid vaccines encoding g protein of respiratory syncytial virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU8427898A AU8427898A (en) | 1999-02-10 |
| AU756222B2 true AU756222B2 (en) | 2003-01-09 |
Family
ID=25406219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU84278/98A Ceased AU756222B2 (en) | 1997-07-18 | 1998-07-16 | Nucleic acid vaccines encoding G protein of respiratory syncytial virus |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0996730A1 (en) |
| JP (1) | JP2001512662A (en) |
| CN (1) | CN1174099C (en) |
| AU (1) | AU756222B2 (en) |
| BR (1) | BR9815496A (en) |
| CA (1) | CA2296089A1 (en) |
| NZ (1) | NZ502626A (en) |
| WO (1) | WO1999004010A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6083925A (en) * | 1995-06-07 | 2000-07-04 | Connaught Laboratories Limited | Nucleic acid respiratory syncytial virus vaccines |
| FR2790959B1 (en) * | 1999-03-15 | 2003-06-27 | Pf Medicament | USE OF BACTERIAL MEMBRANARY FRACTIONS WITH ADJUVANT EFFECT, THEIR PREPARATION METHODS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM |
| FR2798857B1 (en) * | 1999-09-23 | 2003-06-06 | Pf Medicament | USE OF AN OMPA MEMBRANE PROTEIN OF ENTEROBACTERIA ASSOCIATED WITH AN RSV IMMUNOGENIC PEPTIDE FOR THE PREPARATION OF NASAL ADMINISTRATIVE VACCINES |
| DE60040755D1 (en) * | 1999-12-01 | 2008-12-18 | Novartis Vaccines & Diagnostic | RECOGNITION OF ANTIBODIES SPECIFIC TO HEPATITIS C VIRUS (HCV) |
| US7947274B2 (en) | 2007-01-04 | 2011-05-24 | Humabs, LLC. | Human cytomegalovirus neutralising antibodies and use thereof |
| GB0700133D0 (en) | 2007-01-04 | 2007-02-14 | Humabs Llc | Human cytomegalovirus neutralising antibodies and use thereof |
| KR100938105B1 (en) * | 2007-09-21 | 2010-01-21 | 이화여자대학교 산학협력단 | Respiratory Syncytial Virus Vaccine |
| PT3009449T (en) | 2008-07-16 | 2018-09-28 | Inst Res Biomedicine | Human cytomegalovirus neutralizing antibodies and use thereof |
| WO2012053856A2 (en) | 2010-10-21 | 2012-04-26 | 이화여자대학교 산학협력단 | Respiratory syncytial virus vaccine composition and method for preparing same |
| CN111303278B (en) * | 2013-04-15 | 2022-09-06 | 扬森疫苗与预防公司 | Human antibodies binding to RSV G protein |
| AU2020329654A1 (en) * | 2019-08-12 | 2022-03-10 | Advaccine (Suzhou) Biopharmaceuticals Co. Ltd. | Immune composition comprising respiratory syncytial virus (RSV) G polypeptide |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5620896A (en) * | 1992-03-23 | 1997-04-15 | University Of Massachusetts Medical Center | DNA vaccines against rotavirus infections |
-
1998
- 1998-07-16 EP EP98934710A patent/EP0996730A1/en not_active Withdrawn
- 1998-07-16 NZ NZ502626A patent/NZ502626A/en not_active IP Right Cessation
- 1998-07-16 AU AU84278/98A patent/AU756222B2/en not_active Ceased
- 1998-07-16 CA CA002296089A patent/CA2296089A1/en not_active Abandoned
- 1998-07-16 WO PCT/CA1998/000697 patent/WO1999004010A1/en not_active Application Discontinuation
- 1998-07-16 CN CNB988093014A patent/CN1174099C/en not_active Expired - Fee Related
- 1998-07-16 BR BR9815496-6A patent/BR9815496A/en not_active Application Discontinuation
- 1998-07-16 JP JP2000503216A patent/JP2001512662A/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU8427898A (en) | 1999-02-10 |
| WO1999004010A1 (en) | 1999-01-28 |
| NZ502626A (en) | 2002-09-27 |
| BR9815496A (en) | 2001-12-18 |
| JP2001512662A (en) | 2001-08-28 |
| CA2296089A1 (en) | 1999-01-28 |
| EP0996730A1 (en) | 2000-05-03 |
| CN1174099C (en) | 2004-11-03 |
| CN1271389A (en) | 2000-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0832253B9 (en) | Nucleic acid respiratory syncytial virus vaccines | |
| AU778144B2 (en) | Nucleic acid respiratory syncytial virus vaccines | |
| US6428324B1 (en) | RNA respiratory syncytial virus vaccines | |
| JPH03502687A (en) | Respiratory syncytial viruses: vaccines and diagnostics | |
| AU756222B2 (en) | Nucleic acid vaccines encoding G protein of respiratory syncytial virus | |
| AU749345B2 (en) | Alphavirus vectors for paramyxovirus vaccines | |
| US6017897A (en) | Nucleic acid respiratory syncytial virus vaccines | |
| CN110996998A (en) | Recombinant chimeric bovine/human parainfluenza virus 3 expressing RSV G and uses thereof | |
| JP3108095B2 (en) | HRSV vaccine | |
| MXPA00000636A (en) | Nucleic acid vaccines encoding g protein of respiratory syncytial virus | |
| KR20230021115A (en) | Live attenuated respiratory syncytial virus (LIVE ATTENUATED RESPIRATORY SYNCYTIAL VIRUS) | |
| EP1707633A1 (en) | Alphavirus vectors for paramyxovirus vaccines | |
| MXPA00004708A (en) | Alphavirus vectors for paramyxovirus vaccines | |
| MXPA00002236A (en) | Rna respiratory syncytial virus vaccines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |